Research programme: nerve agent antidotes - Countervail Corporation

Drug Profile

Research programme: nerve agent antidotes - Countervail Corporation

Alternative Names: AverTox; Galantamine - Countervail Corporation

Latest Information Update: 15 Aug 2016

Price : $50

At a glance

  • Originator University of Maryland, Baltimore
  • Developer Countervail Corporation
  • Class
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Poisoning

Most Recent Events

  • 19 Nov 2008 Pharmacodynamics data from an animal study in poisoning presented at the 38th Annual Meeting for the Society of Neuroscience (SfN-2008)
  • 02 Oct 2007 Preclinical trials in Poisoning in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top